perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Severe disease is not essential for a high neutralizing 1 antibody response post-SARS-CoV-2 infection 2

3

Afrah Khairallah¹, Zesuliwe Jule¹, Alice Piller¹, Mallory Bernstein¹, Kajal Reedoy¹, 4 Yashica Ganga¹, Bernadett I. Gosnell², Farina Karim¹, Yunus Moosa², Thumbi 5 Ndung'u^{1,3,4,5}, Khadija Khan¹, Alex Sigal^{1,6} 6

7 ¹Africa Health Research Institute and University of KwaZulu-Natal, Durban, South Africa. ²Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, 8 9 Durban, South Africa .³HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South 10 Africa. ⁴Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and 11 Harvard University, Cambridge, MA, USA. ⁵Division of Infection and Immunity, University College 12 London, London, UK. ⁶The Lautenberg Center for Immunology and Cancer Research, Faculty of 13 Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

14

Neutralizing antibody responses correlate with protection from SARS-CoV-2 infection, 15 16 yet higher neutralizing responses associate with more severe disease. Whether people without severe disease can also develop strong neutralizing responses to infection, 17 and the pathways involved, is less clear. We performed a proteomic analysis on sera 18 from 71 individuals infected with ancestral SARS-CoV-2, enrolled during the first South 19 African infection wave. We determined disease severity by whether participants 20 21 required supplemental oxygen and measured neutralizing antibody levels at convalescence. High neutralizing antibodies were associated with high disease 22 23 severity, yet 40% of participants with lower disease severity had neutralizing antibody 24 levels comparable to those with severe disease. We found 130 differentially expressed proteins between high and low neutralizers and 40 between people with high versus 25 low disease severity. Five proteins overlapped, including furin, a protease which 26 enhances SARS-CoV-2 infection. High neutralizers with non-severe disease had similar 27 levels of differentially expressed neutralization response proteins to high neutralizers 28 with severe disease, yet similar levels of differentially expressed disease severity 29 30 proteins to participants with non-severe disease. Furthermore, we could reasonably 31 predict who developed a strong neutralizing response based on a single protein, HSPA8, involved in clathrin pit uncoating. These results indicate that a strong antibody 32 response does not always require severe disease and may involve different pathways. 33

34

Introduction 35

Many transient viral infections elicit a neutralizing antibody response which not only helps to 36 37 clear the virus, but also protects convalescent individual from re-infection¹. This has been shown for SARS-CoV-2, and until the Omicron variant emerged, re-infection was rare². 38 39 Binding of neutralizing antibodies prevents the viral spike protein from accessing the 40 angiotensin-converting enzyme 2 (ACE2) viral receptor³. Neutralizing antibody levels strongly correlate with the degree of vaccine mediated protection⁴⁻⁷. 41

Factors predisposing to higher disease severity and mortality in Covid-19 include male sex, 42 diabetes, hypertension, and HIV²². Higher disease severity results in higher neutralizing 43 antipadiy peyels in SARS-Cov-2, infection⁸⁻¹⁹ in contrast asymptomatic sinfection associates 44

with a low neutralizing antibody response^{20,21}. This opens the question of whether severe 45 disease is necessary for a robust antibody response. An alternative is that both are driven by 46 shared factors such as high viral titers or prolonged infection²³. Given that severe Covid-19 is 47 due to lower respiratory tract infection, which causes acute respiratory distress syndrome 48 (ARDS) from aberrant inflammation interfering with gas exchange^{24,25}, it is possible that a more 49 50 controlled immune response could avoid ARDS while still being sufficiently robust to elicit high neutralizing antibody levels. 51

Here, we asked whether severe Covid-19 is required for high neutralizing antibody levels post-52 infection. To avoid confounding the results with re-infection and vaccination, we selected 53 individuals from our cohort²⁶ who were infected by ancestral SARS-CoV-2 in the first Covid-54 19 infection wave in South Africa, before vaccination was available and variants arose. Given 55 56 the rarity of reinfection pre-Omicron²⁷, the infections we studied were very likely first exposures to SARS-CoV-2. We separated participants with Covid-19 into higher severity versus lower 57 58 severity by whether participants required supplemental oxygen. The requirement for 59 supplemental oxygen is a key measure in ordinal scales like that used by the World Health Organization²⁸. We used proteomics to examine the differentially regulated proteins and 60 pathways in people with different combinations of disease severity and antibody response. 61

62 We observed that, while higher severity cases tended to make strong antibody responses, a subset of participants with more mild disease who did not require supplemental oxygen also 63 64 showed high neutralizing antibody levels. There was minor overlap between the differentially 65 expressed proteins associated with severity versus those associated with the neutralizing antibody response. Additionally, levels of heat shock protein family A member 8 (HSPA8) 66 emerged as predictive of neutralizing responses. 67

68

69 Results

70 **Cohort characteristics**

We enrolled 72 participants infected during the first SARS-CoV-2 infection wave in Durban 71 South Africa lasting from March to October 2020²⁹ (Figure 1, Table 1). One participant in the 72 cohort had immunosuppression due to advanced HIV disease with a CD4 count of 6 at 73 74 enrollment and an HIV viral load of 34,151 copies/mL. This participant did not make a 75 neutralizing antibody response and had persistent SARS-CoV-2 infection, as described in our previous work²⁹⁻³¹. Because of the outlier immune state, we excluded this participant from 76 77 further analysis and analyzed results for 71 participants.

78 We scored disease severity by whether the participant required supplemental oxygen^{26,28}. Participants were classified into the less severe (no supplemental oxygen) and more severe 79 80 (supplemental oxygen) groups. For brevity, we refer to these groups as "non-severe" and 81 "severe", although we recognize there may be gradations of severity within each group. Demographics and comorbidities were recorded. We determined HIV status, HIV viral load, 82 and CD4 T cell concentrations in the blood. Diagnosis of SARS-CoV-2 infection was performed 83 84 by qPCR. Participants were enrolled a median of 6 days (IQR 4-8 days) post-diagnosis. A quantitative SARS-CoV-2 titer was not available. We performed the first sampling at 85 enrollment (Figure 1). This sample was used for proteomic analysis as well as to measure 86 lymphocytes, neutrophils, CD4 T cell numbers, HIV status, and HIV viral load. 87

A second sample was taken a median of 32 days (IQR 17-35 days) post-diagnosis, at a time 88 when the infection elicited antibody response should be close to its peak¹⁶. This sample was 89 90 used to measure neutralizing antibody levels by a live virus focus reduction neutralization test

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

91 (FRNT^{32,33}). Fifty-five participants (76%) were determined to have non-severe disease because they did not require supplemental oxygen, and 17 (24%) were classified as severe. 92 People living with HIV (PLWH) accounted for 47% of the participants, reflecting the high HIV 93 prevalence in the province of KwaZulu-Natal in South Africa where Durban is located³⁴. 94

CD4 T cell count was a median of 590 cells/µL (IQR 340-940) at enrollment over the entire 95 96 participant group and was significantly lower (p=0.0072 by the Mann-Whitney U test, Table 1) 97 in the severe (380 cells/µL, IQR 270-590) relative to the non-severe (700 cells/µL, IQR 470-1100) group. The lower CD4 count in severe disease is expected because severe disease 98 often results in lymphopenia³⁵⁻³⁷. The CD4 count increased upon convalescence at the second 99 visit to a median of 830 cells/µL (IQR 510-1100), and there was no significant difference 100 101 between the severe (820 cells/µL, IQR 530-1100) and non-severe (840 cells/µL, IQR 390-900) 102 groups (Table 1).

Increased neutrophils are associated with severe disease^{26,37-39} and the neutrophil to 103 lymphocyte ratio (NLR) was significantly higher in the severe group in the first visit (4.2 vs. 104 1.9, p=0.04 by the Mann-Whitney U test, see Table 1). The NLR dropped and was similar in 105 both groups at the second, convalescence visit (Table 1). The severe group had significantly 106 higher levels of neutralizing antibodies, as measured by the $FRNT_{50}$, which is the inverse 107 108 serum dilution in the FRNT assay required to neutralize 50% of ancestral SARS-CoV-2 (Table 109 1).

110

Categorization of participants into high and low neutralizers and association with risk factors 111

We used the median FRNT₅₀ neutralization level (FRNT₅₀=358) to categorize participants into 112 high and low neutralizers. Our justification for using the median is that it is simple yet gives 113 two groups which are strongly distinct in neutralization capacity: Geometric mean titer (GMT) 114 115 FRNT₅₀ values were 1348 in the high neutralizer group (n=35) versus 46 in the low neutralizer group (n=36), a 29-fold drop (Figure 2A). The number of participants in the non-severe disease 116 group was 55, out of which 33 were low neutralizers, while 22 were high neutralizers (Table 117 2). Out of the 16 participants in the high severity group, 13 were high neutralizers while the 118 remaining 3 were low neutralizers (Table 2). 119

120

121 The frequency of participants with high disease severity was significantly higher in the high 122 neutralization group relative to the low neutralization group (p=0.0046 by Fisher's Exact test, Figure 2B). However, as presented in Table 2, the majority of the 35 participants in the high 123 neutralizer group were non-severe (22 participants, versus 13 with high severity). There was 124 125 no significant difference in neutralizing antibody levels between participants with high disease 126 severity and high neutralizers with low disease severity (Figure S1).

127

High NLR, comorbidities, and being male was associated with higher neutralization in 128 univariate analysis. The frequency of individuals with high NLR (>6)³⁸, was significantly higher 129 in the high neutralization group (p=0.011 by Fisher's Exact test, Figure 2C). The frequency of 130 individuals with recorded comorbidities (hypertension and/or diabetes) was also significantly 131 132 higher in the high neutralizer group (p=0.00018 by Fisher's Exact test, Figure 2D). Males were significantly more frequent among the high neutralizers (p=0.042 by Fisher's Exact test, Figure 133 134 2E). In contrast, there was no significant difference between the frequency of PLWH versus HIV negative people between the high and low neutralizer groups (Figure 2F). Univariate 135 analysis showed significantly increased odds (odds ratio (OR) >1) of being a high neutralizer 136 with severe disease, comorbidities, high NLR, and being male (Figure 2G). In multivariate 137 analysis, only severe disease and comorbidities remained significant (Figure 2H, with exact 138

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

139 numbers and confidence intervals in Table S1). People who both required supplemental oxygen and had comorbidities appeared only in the high neutralizer group (Figure S2). 140 However, the largest subgroup in the high neutralizer group consisted of people with non-141 severe disease without comorbidities (Figure S2). 142

- 143
- 144 Differentially expressed proteins between high and low neutralizers
- 145

We used SomaScan proteomics⁴⁰ to determine the levels of ~5000 proteins in participant 146 plasma from the blood sample collected at enrollment. Differentially expressed proteins 147 148 (DEPs) were identified as those with a ≥1.5-fold decrease or increase in mean expression in one group relative to the other, with a p-value corrected by the false discovery rate (FDR) of 149 150 $<0.05^{41-43}$. We obtained 130 significant DEPs when comparing the high versus the low neutralizer groups (Figure 3A) and 40 DEPs when comparing the non-severe versus the 151 152 severe disease groups (Figure 3B).

153

Examples of DEPs with higher levels in high versus low neutralizers (Figure 3A) included 154 HSPA8, also called HSC70⁴⁴. This protein is a chaperone from the HSP70 family of 155 constitutively expressed heat shock proteins and has multiple functions including clathrin 156 uncoating during clathrin-mediated endocytosis⁴⁵, antigen presentation on MHC class II 157 molecules^{44,46}, and autophagy⁴⁴. It interacts with proteins from multiple viruses, including the 158 SARS-CoV-2 spike⁴⁷, the influenza M1⁴⁸, and the papillomavirus L2⁴⁹ proteins. Another DEP 159 160 with significantly higher levels in high neutralizers was von Willebrand factor (VWF), involved 161 in orchestrating the coagulation response⁴⁷.

162

Furin was an example of a significant DEP in severe versus non-severe disease (Figure 3B). 163 164 Furin is a protease which promotes SARS-CoV-2 cellular infection by cleaving the S1/S2 polybasic site and therefore facilitating viral fusion⁵⁰. Furin was also elevated in high versus 165 low neutralizers. Another infection promoting factor with higher levels in the high disease 166 167 severity group was Calpain-2 (CAPN2), involved in positively regulating the cell surface levels of the ACE2 receptor ⁵¹. 168

169

Only five DEPs were found to overlap between the neutralization and disease severity 170 conditions (Figure 3C, proteins marked in green in Figure 3A-B). Upregulated DEPs in 171 common to both high neutralization and high disease severity were furin, DNAse1L2, and 172 173 endoplasmic reticulum protein 44 (Erp44). Downregulated DEPs in common were anthrax toxin receptor-2 (ANTXR2) and amyloid beta precursor like protein 1 (APLP1). DNAse1L2 has 174 been shown to be transcriptionally activated by inflammatory cytokines⁵² resulting from 175 infection. Erp44, a protein from the thioredoxin family, is upregulated by endoplasmic reticulum 176 stress⁵³ and has been reported to be a target of SARS-CoV-2 ORF8⁵⁴. ANTXR2, the receptor 177 178 for the anthrax toxin, is involved in angiogenesis and cell adhesion⁵⁵. APLP1 is required for glucose homeostasis⁵⁶, and its downregulation is associated with neurological symptoms of 179 Covid-19⁵⁷. 180

181

Gene set enrichment analysis of differentially regulated pathways in neutralization and disease 182 severity 183

184

We used Gene Set Enrichment Analysis (GSEA)⁵⁸ to determine the differentially regulated 185 pathways between high and low neutralizers and participants with severe versus non-severe 186 187 disease (Figure 4). We used the Molecular Signatures Database (MSigDB) Hallmark gene

set⁵⁹ and a significance threshold of FDR < 0.1 to determine significantly enriched pathways. 188

189 We found 7 upregulated pathways and 1 downregulated pathway in high versus low neutralizers. We found 4 upregulated pathways and 1 downregulated pathway in severe 190 versus non-severe participants. There was one upregulated pathway in common. 191

- 193 In high neutralizers, the upregulated pathways were adipogenesis, the interferon- α (IFN- α) 194 response, PI3k/Akt/mTOR signaling, oxidative phosphorylation, mTORC1 signaling, and xenobiotic metabolism. The downregulated pathway was hedgehog signaling. The pathways 195 196 upregulated in the high versus low severity groups were glycolysis, the UV response, and the unfolded protein response. Spermatogenesis was downregulated. Similarly to analysis of 197 198 individual DEPs, there was no extensive overlap in the pathways between responses. The single pathway upregulated in common between the high versus low neutralizers and severe 199 200 versus non-severe disease was fatty acid metabolism.
- 201

203

192

202 High neutralizers showed similar DEP levels regardless of severity

To better understand differences between high neutralizers with severe versus non-severe 204 205 disease, we examined the top 20 most significant by FDR DEPs in the neutralization response 206 to determine whether they are similarly or differently regulated in high neutralizers with high versus low disease severity (Figure 5). They included fibroblast activation protein- α (FAP), a 207 serine protease involved in tissue remodeling⁶⁰, motilin (MLN), a hormone promoting 208 gastrointestinal motility⁶¹, and ribosome-binding protein 1 (RRBP1), involved in the 209 210 endoplasmic reticulum stress response⁶².

211

212 In 14 of these DEPs including FAP, MLN, and RRBP1, levels were not significantly different between high neutralizers with non-severe disease and high neutralizers with severe disease. 213 214 Both groups had a significantly different level of DEPs relative to the low neutralizer group 215 (Figure 5). For the remaining six proteins, the high neutralizer group with non-severe disease displayed intermediate expression, between high neutralizers with severe disease and the low 216 217 neutralizers. This group included 3 of the 5 proteins which were in common between the 218 neutralization response and disease severity (furin, ANTXR2, and DNAse1L2), as well as VWF and HSPA8. These results indicate that high neutralizers have levels of the 20 most 219 220 significant neutralization related DEPs which are generally similar regardless of disease 221 severity.

- 222
- 223 224

HSPA8 level predicts whether infection will elicit high levels of neutralizing antibodies

We investigated whether we could predict strong neutralizing antibody responses based on 225 226 the DEPs significantly associated with neutralization level. Participants were split into training 227 (60%, n=42) and test (40%, n=29) groups. Significantly regulated proteins were determined 228 by the same FDR and fold-change cut-off as used in the full set analysis (FDR<0.05, fold change≥1.5), resulting in 12 significantly regulated proteins in the neutralization response in 229 230 the training set (Figure S3). Repeated stepwise regression using bootstrapping was performed to rank the predictive power of each of the 12 proteins by iteratively subtracting or adding each 231 of the proteins from/to the model. Stepwise regression was performed until the Akaike 232 233 information criterion (AIC), a measure of the trade-off between goodness-of-fit and model 234 complexity was optimized. The top three predictive proteins in order of significance were HSPA8, MLN, and FAP. They were combined in a multivariate logistic regression model 235 (Figure 6A) and analyzed singly in univariate regression (Figure 6B-D). 236

237

The combination of HSPA8, MLN, and FAP resulted in good discrimination between high 238 239 neutralizers versus low neutralizers, showing an area under the curve (AUC) of 0.91 (Figure

240 6A). Using HSPA8 alone, the model could reasonably distinguish between low and high neutralization outcomes in the test group (AUC=0.86, p=0.0018, Figure 6B). The predictive 241 power of FAP (AUC=0.84) and MLN (AUC=0.79) was slightly lower (Figure 6C-D). 242

243

Similar severity related protein levels in high and low neutralizers with non-severe disease 244

245 Lastly, to test whether the similarity in disease severity between low and high neutralizers with 246 247 non-severe disease was supported by the similarity in protein expression of severity-related proteins, we examined the top 20 significant by FDR proteins that were differentially expressed 248 249 in the severe versus the non-severe groups. Included in this group was CAPN2, which increases the levels of the SARS-CoV-2 receptor ACE2⁵¹, and CD79A, a marker of B cell 250 251 activation reported to be upregulated upon SARS-CoV-2 infection⁶³.

252

253 We found that for 16 out of the top 20 DEPs examined, the expression level was not 254 significantly different between the high and low neutralizers among the participants with nonsevere disease (Figure 7). In addition, in all but two of the 16 proteins, there was a significant 255 256 difference between both the high and low neutralizers with non-severe disease and the severe 257 disease group. In 3 out of the remaining 4 DEPs which did not follow this pattern (furin, ANTXR2, and DNAse1L2), the non-severe high neutralizers had intermediate protein levels 258 which fell between the non-severe low neutralizers and the severe disease group. 259 Interestingly, these DEPs were also common to both the severity and neutralization responses 260 261 (Figure 3A-B). The fourth DEP, olfactomedin 2 (OLFM2), a protein mostly expressed in 262 neurons and found to regulate metabolism⁶⁴, did not show a significant difference between the non-severe high neutralizers and the severe disease group (Figure 7). These results indicate 263 that, for the majority of the top 20 DEPs by significance which distinguished severe from non-264 265 severe disease participants, levels were similar between non-severe participants, regardless of participant neutralization capacity. 266

267

268 Discussion

269

We investigated disease severity, proteomic profiles, and infection-elicited neutralizing 270 antibody levels in a cohort of 71 South African people infected with SARS-CoV-2 during the 271 272 first ancestral SARS-CoV-2 infection wave. We stratified our cohort into severe and nonsevere disease based on whether participants required supplemental oxygen and separated 273 274 participants into high neutralizers and low neutralizers at convalescence based on their plasma neutralization capacity of ancestral SARS-CoV-2. We found that high disease severity 275 276 and comorbidities were significantly associated with high neutralization capacity. However, 277 there were participants with non-severe disease who had had similarly high neutralizing 278 antibody levels to those with severe disease. These non-severe high neutralizers showed 279 similar differentially expressed neutralization response protein levels to high neutralizers with 280 severe disease. Meanwhile, their levels of differentially expressed proteins involved in disease 281 severity were similar to participants with non-severe disease.

282

The enriched pathways we observed in high versus low neutralizers were generally associated 283 284 with viral replication or the immune response. These included the interferon- α (IFN- α) 285 response, a key part of the innate immune response to viral infections, with rapid production of IFN-α triggering antiviral and pro-inflammatory effects⁶⁵; PI3k/Akt/mTOR signaling, which is 286 is a mediator of cell cycle progression and cell survival⁶⁶, with activation increasing viral 287 replication⁶⁷⁻⁶⁹; Oxidative phosphorylation (OXPHOS), the process by which mitochondria 288 generate ATP, with SARS-CoV-2 infection has been reported to promote OXPHOS and 289 290 increases ATP production⁷⁰; the mTORC1 pathway, a metabolic regulator of cell growth⁷¹, with

perpetuity. It is made available under a CC-BY-ND 4.0 International license.

mTORC1 inhibitors shown to reduce SARS-CoV-2 replication⁷²; hedgehog signaling, involved 291 in development, cell proliferation, survival, and immune regulation, and modulated by multiple 292 viruses⁷³; fatty acid metabolism, the pathway in common between the neutralization response 293 and disease severity, essential for the replication of enveloped viruses⁷⁴⁻⁷⁶. The other enriched 294 pathways in the neutralization response may be associated with higher disease severity, 295 296 although they do not come up as enriched pathways in the severe versus non-severe disease analysis: adipogenesis, associated with obesity, a known risk factor for severe Covid-1977-80, 297 298 and upregulation of xenobiotic metabolism, which may indicate the presence of pharmacological interventions⁸¹. 299

300

Like with the neutralization response, the enriched pathways in severe versus non-severe 301 302 disease show links to SARS-CoV-2 replication. However, some make sense as consequences of severe disease independently of such replication. Thus, the upregulated pathway of 303 304 glycolysis increases the replication of SARS-CoV-2 and other viruses⁸²⁻⁸⁴. However, hypoxia, which may have been present in participants with respiratory distress who required 305 supplemental oxygen, also results in a metabolic switch from mitochondrial respiration to 306 increased glycolysis⁸⁵. The unfolded protein response may be upregulated because of the 307 increased production of improperly folded proteins due to ER stress during SARS-CoV-2 308 309 cellular infection⁸⁶. Interestingly, ER stress and misfolded proteins have also been linked to autoimmune disease⁸⁷, which has been reported to be elevated post-Covid-19⁸⁸. Upregulation 310 of proteins involved in the UV response may be because SARS-CoV-2 induces cell cycle 311 arrest to gain cellular resources⁸⁹. Decreased spermatogenesis, on the other hand, has been 312 313 previously shown to be a consequence of severe Covid-19 leading to death⁹¹.

314

For the neutralization response, differentially expressed proteins were measured at an earlier 315 316 point in time than the neutralizing antibody response is thought to develop⁹². Therefore, they 317 may be predictive. We found that three proteins, HSPA8, MLN, and FAP, could predict who will be high neutralizers. The best single protein predictor was HSPA8. This protein has 318 319 multiple roles in cellular homeostasis, including a key role in the uncoating of endocytosed clathrin vesicles⁹³. Interestingly, clathrin mediated endocytosis is a major cellular infection 320 pathway for SARS-CoV-2⁹⁴ and facilitation of this process by HSPA8 may increase viral 321 replication. In addition, HSPA8 has an important role in antigen presentation on MHC class II 322 molecules^{44,46}, a necessary step in the CD4 helper T cell - B cell interactions which are 323 responsible for the production of effective neutralizing antibodies⁹⁵. 324 325

There was minor overlap between differentially expressed proteins and pathways involved in 326 327 the neutralization response and the disease severity response. The minor overlap argues 328 against the direct dependence of neutralizing antibody levels on disease severity and supports the proposition that a common factor such as high or prolonged viral replication results in both 329 330 higher infection-elicited neutralization capacity and higher disease severity. However, a limitation to this conclusion is that, because of small group sizes, some differentially expressed 331 332 proteins did not reach statistical significance in the disease severity response. For example, coagulation factor VWF was significantly higher in high neutralizers (FDR = 0.0001) but 333 narrowly missed statistical significance in disease severity (FDR = 0.055). VWF was 334 previously reported to be upregulated in high disease severity⁹⁶. A second limitation is that our 335 336 single measure, the requirement for supplemental oxygen, does not capture the range of more versus less severe disease, and therefore disease severity for some participants is 337 misclassified. Nevertheless, while supplemental oxygen is not a perfect measure, most people 338 with severe disease have respiratory failure, although they may die from multiorgan failure or 339 other reasons^{97,98}. The presence of non-severe high neutralizers, who have similar 340

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

341 neutralization response related protein profiles to severe high neutralizers, may mean that high disease severity is not essential to elicit a robust neutralizing antibody response. 342

- 343
- 344 Methods

Informed consent and ethical statement 345

This was an observational study with longitudinal sample collection. The nasopharyngeal 346 swab used to isolate ancestral SARS-CoV-2 as well as all blood samples were obtained after 347 348 written informed consent from adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective cohort of SARS-CoV-2 infected individuals at the Africa Health Research Institute. 349 350 The study protocol was approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001275/2020). Participants were reimbursed 351 for each visit based on time, inconvenience and expenses as approved in the protocol. 352

353 Clinical laboratory testing

CD4 T cell count and HIV viral load quantification were performed from a 4mL EDTA tube of 354 blood at an accredited diagnostic laboratory (Ampath for CD4 and Molecular Diagnostic 355 356 Services for HIV viral load, both based in Durban, South Africa).

357 Cells

The VeroE6 cells expressing TMPRSS2 and ACE2 (Vero E6-TMPRSS2), originally BEI 358 Resources, NR-54970, were used for virus expansion and live virus neutralization assays. The 359 360 cell line was propagated in growth medium consisting of Dulbecco's Modified Eagle Medium (DMEM, Gibco 41965-039) with 10% fetal bovine serum (Hyclone, SV30160.03) containing 361 10mM of hydroxyethylpiperazine ethanesulfonic acid (HEPES, Lonza, 17-737E), 1mM sodium 362 pyruvate (Gibco, 11360-039), 2mM L-glutamine (Lonza BE17-605E) and 0.1mM nonessential 363 364 amino acids (Lonza 13-114E).

Live virus neutralization assay (focus reduction neutralization assay) 365

For all neutralization assays, viral input was 100 focus forming units per well of a 96-well plate. 366 VeroE6-TMPRSS2 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day 367 pre-infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 368 × g for 10 min and stored at -80 °C. Aliquots of plasma samples were heat-inactivated at 56 °C 369 for 30 minutes and clarified by centrifugation at 10,000 × g for 5 minutes. Virus stocks were 370 371 added to serially diluted plasma in a 96-well plate (Corning) and antibody-virus mixtures were incubated for 1 h at 37 °C, 5% CO₂. Cells were infected with 100 µL of the virus-antibody 372 mixtures for 1 h, then 100 µL of a 1X RPMI 1640 (Sigma-Aldrich, R6504), 1.5% 373 carboxymethylcellulose (Sigma-Aldrich, C4888) overlay was added without removing the 374 375 inoculum. Cells were fixed 20 h post-infection using 4% PFA (Sigma-Aldrich, P6148) for 20 376 min. Foci were stained with a rabbit anti-spike monoclonal antibody (BS-R2B12, GenScript A02058) at 0.5 µg/mL in a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich, 377 378 S7900), 0.1% BSA (Biowest, P6154) and 0.05% Tween-20 (Sigma-Aldrich, P9416) in PBS for 2 h at room temperature with shaking, then washed with wash buffer containing 0.05% Tween-379 20 in PBS. Secondary goat anti-rabbit HRP conjugated antibody (Abcam ab205718) was 380 381 added at 1 µg/mL and incubated for 2 h at room temperature with shaking. TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50 µL per well and incubated 382 383 for 20 min at room temperature. Plates were imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot Professional built-in image analysis (C.T.L). 384

Statistics and fitting 385

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

386 All statistics were performed in GraphPad Prism version 9.4.1. All fitting to determine FRNT₅₀ and linear regression was performed using custom code in MATLAB v.2019b (FRNT₅₀) or the 387 fit Im function for linear regression, which was also used to determine goodness-of-fit (R²) as 388 well as p-value by F-test of the linear model. Limits of quantification were between 1:25 (most 389 390 concentrated plasma used and 1:3200 (most dilute plasma used)

391 Neutralization data were fit to:

$$392 \quad Tx = 1/1 + (D/ID_{50}). \tag{1}$$

Here Tx is the number of foci at plasma dilution D normalized to the number of foci in the 393 absence of plasma on the same plate. ID_{50} is the plasma dilution, giving 50% neutralization. 394 $FRNT_{50} = 1/ID_{50}$. Values of $FRNT_{50} < 1$ are set to 1 (undiluted), the lowest measurable value. 395 We note that $FRNT_{50} < 25$ or $FRNT_{50} > 3200$ fell outside of the dilution series used and were 396 extrapolated from the fit. 397

398 Plasma proteomic profiling

399 Proteomic analysis of the plasma samples was performed by SomaLogic, Inc. (Boulder, CO, USA) using the SomaScan v4.0 platform⁹⁹. The SomaScan measures were reported as 400 relative fluorescence units (RFU) in a summary ADAT file. These data were then merged with 401 402 our metadata. Quantile normalization and log transformation were performed on all RFUreported data to ensure comparability and normalization across samples. 403

Differential protein analysis 404

The proteome changes attributable to both neutralization capacity and disease severity were 405 derived from comparisons between individuals with high versus low neutralization capacity 406 407 and severe versus non-severe outcomes, respectively. Protein data were log-transformed 408 before testing the difference in means between comparison groups using the Student's t-test. P-values were corrected to control for the false discovery rate (FDR)¹⁰⁰. The absolute fold 409 change was rounded up to one decimal place (i.e, fold change values between 1.4 and 1.5 410 were rounded to 1.5). Proteins with an adjusted p-value < 0.05 and absolute fold change ≥1.5 411 412 were considered differentially expressed. These differentially expressed proteins were then visualized using a volcano plot in the R Project for statistical computing and graphical 413 representation. 414

Gene set enrichment analysis 415

Gene Set Enrichment Analysis (GSEA) was performed using the Broad Institute GSEA 416 417 software version 4.3.3^{58,101}, the MSigDB Hallmark gene sets (v2023.2), and the UniProt Human Collection chip platform. The GSEA software was downloaded from https://www.gsea-418 419 msigdb.org/gsea/downloads.jsp, and GSEA was performed using default parameter settings 420 except for Number of permutations = 10,000; Permutation type = gene set; $10 \le$ gene set size 421 ≤ 500.

422

Analysis of top variable proteins in the neutralization and severity responses 423

The top 20 variable proteins from the differential protein analysis of the neutralization response 424 425 were selected based on FDR value. The proteins were standardized using Z-score normalization, where the mean level of a given protein is subtracted from each value of that 426 427 protein, and the difference is divided by the protein's standard deviation. Pairwise differences in median protein levels between high neutralizers with severe disease, high neutralizers with 428 non-severe disease, and low neutralizers (severe and non-severe) were assessed using 429 430 Mann-Whitney U tests, with p-values adjusted for multiple comparisons using the Benjamini-

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

431 Hochberg method. Adjusted p-values < 0.05 were marked as significant. Outliers (absolute Zscore > 3) were included in the analysis but excluded from the plot for clarity of the 432 visualization. The same analysis was carried out on the top 20 variable proteins in the severity 433 434 response, except pairwise differences assessed were between severe disease (high and low neutralizers), non-severe high neutralizers, and non-severe low neutralizers. 435

436 Logistic regression prediction model of neutralization outcome

Participants were split into training (60%, n=42) and testing (40%, n=29) sets. To identify a 437 438 subset of proteins with the most potential predictive power of neutralization outcome, the training data were subjected to differential protein analysis as described above. This yielded 439 440 12 significantly differentially expressed proteins (DEPs) between high and low neutralizers in 441 the training data. The protein data in the training and testing sets were log-transformed and 442 scaled by subtracting the mean and dividing by the standard deviation, with the mean and 443 standard deviation of the training data used for both the training and testing sets. Using bootstrapping (1000 iterations with 100 participant values drawn with replacement per 444 445 iteration), the neutralization response was iteratively modeled against the 12 DEPs and 446 subjected to forward and backward stepwise regression, selecting the most significant predictors in a regression model by adding (forward) or subtracting (backward) predictors in a 447 448 stepwise manner, optimizing for Akaike's information criterion (AIC). With each bootstrap iteration, the proteins selected by stepwise regression were added to a running tally, which 449 450 served to rank the predictive power of the 12 DEPs upon completion of the bootstrapping. 451 Neutralization response was fitted against the top three ranked proteins, MLN, FAP, and 452 HSPA8, in a binomial logistic regression model, which was trained using the training data. The performance of this multivariate model and the constituent univariate models was assessed 453 454 using the testing data of ROC curves, and AUC statistics were generated using the R pROC package. 455

456 Data availability

The ancestral SARS-CoV-2 isolate used in this study for the neutralization assays has been 457 deposited in GISAID and GenBank with accession numbers EPI ISL 602626.1 (GISAID), 458 OP090658 (GenBank). It is available upon reasonable request. All R-scripts used in the 459 analysis have been deposited to GitHub (https://github.com/Afrah-Khairallah/Omics-). 460

461 **Author contributions**

A.S., A.K., and K.K. conceived the study and designed the study and experiments. Z.J., K.R. 462 Y.G., B.I.G, F.K., Y.M., and K.K identified and provided samples and performed the 463 464 neutralization experiments. T.N. provided resources. A.P., A.K., and A.S., and M.B. analyzed the data. A.S., A.P., and A.K. prepared the manuscript with input from all authors. 465

Acknowledgements 466

We thank Clare Paterson and the team at SomaLogic for performing the proteomics and for 467 468 helpful comments on the manuscript.

Funding 469

This study was supported by the Bill and Melinda Gates award INV-018944 (AS) and the Bill 470 471 and Melinda Gates Global Health Discovery Collaboratory.

473 References

474

1 475 Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-476 CoV-2 infection and COVID-19 disease. Immunol Rev 310, 6-26 (2022). PMC9348242. 477 10.1111/imr.13091

478

483

489

- 479 2 Pulliam, J. R. C., van Schalkwyk, C., Govender, N., von Gottberg, A., Cohen, C., Groome, 480 M. J., Dushoff, J., Mlisana, K. & Moultrie, H. Increased risk of SARS-CoV-2 reinfection 481 associated with emergence of Omicron in South Africa. Science 376, eabn4947 (2022). PMC8995029. 10.1126/science.abn4947 482
- 484 3 Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K. A., Esswein, S. R., Gristick, H. B., 485 Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., 486 Nussenzweig, M. C., West, A. P., Jr. & Bjorkman, P. J. SARS-CoV-2 neutralizing antibody 487 structures inform therapeutic strategies. Nature 588, 682-687 (2020). PMC8092461. 488 10.1038/s41586-020-2852-1
- 490 4 Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A. & Davenport, M. P. Neutralizing antibody levels are 491 492 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat 493 Med 27, 1205-1211 (2021). 10.1038/s41591-021-01377-8
- 494 495 5 Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., 496 Triccas, J. A., Khoury, D. S. & Davenport, M. P. Neutralising antibody titres as predictors 497 of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. 498 The Lancet Microbe 3, e52-e61 (2022).
- 499 6 Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. 500 R., Dull, P. & Plotkin, S. A. Evidence for antibody as a protective correlate for COVID-19 501 vaccines. Vaccine 39, 4423-4428 (2021). PMC8142841. 10.1016/j.vaccine.2021.05.063
- 503 7 Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Khan, S. R., Sasson, S. C., Kent, S. J., Khoury, D. S. & Davenport, M. P. Predicting vaccine effectiveness against severe COVID-504 19 over time and against variants: a meta-analysis. Nat Commun 14, 1633 (2023). 505 506 PMC10036966. 10.1038/s41467-023-37176-7
- 507 508 8 Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., 509 Hauser, B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G., 510 Charles, R. C., Dighe, A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G., 511 lafrate, A. J. & Balazs, A. B. COVID-19-neutralizing antibodies predict disease severity 512 and survival. Cell 184, 476-488.e411 (2021). PMC7837114. 10.1016/j.cell.2020.12.015
- 513 514 9 Lucas, C., Klein, J., Sundaram, M. E., Liu, F., Wong, P., Silva, J., Mao, T., Oh, J. E., 515 Mohanty, S., Huang, J., Tokuyama, M., Lu, P., Venkataraman, A., Park, A., Israelow, B., 516 Vogels, C. B. F., Muenker, M. C., Chang, C. H., Casanovas-Massana, A., Moore, A. J., Zell, 517 J., Fournier, J. B., Obaid, A., Robertson, A. J., Lu-Culligan, A., Zhao, A., Nelson, A., Brito, 518 A., Nunez, A., Martin, A., Watkins, A. E., Geng, B., Chun, C. J., Kalinich, C. C., Harden, C.

519 520 521 522 523 524 525 526 527 528 529 530		A., Todeasa, C., Jensen, C., Dorgay, C. E., Kim, D., McDonald, D., Shepard, D., Courchaine, E., White, E. B., Song, E., Silva, E., Kudo, E., Deluliis, G., Rahming, H., Park, HJ., Matos, I., Ott, I., Nouws, J., Valdez, J., Fauver, J., Lim, J., Rose, KA., Anastasio, K., Brower, K., Glick, L., Sharma, L., Sewanan, L., Knaggs, L., Minasyan, M., Batsu, M., Petrone, M., Kuang, M., Nakahata, M., Linehan, M., Askenase, M. H., Simonov, M., Smolgovsky, M., Balkcom, N. C., Sonnert, N., Naushad, N., Vijayakumar, P., Martinello, R., Datta, R., Handoko, R., Bermejo, S., Prophet, S., Bickerton, S., Velazquez, S., Alpert, T., Rice, T., Khoury-Hanold, W., Peng, X., Yang, Y., Cao, Y., Strong, Y., Lin, Z., Wyllie, A. L., Campbell, M., Lee, A. I., Chun, H. J., Grubaugh, N. D., Schulz, W. L., Farhadian, S., Dela Cruz, C., Ring, A. M., Shaw, A. C., Wisnewski, A. V., Yildirim, I., Ko, A. I., Omer, S. B., Iwasaki, A. & Yale, I. R. T. Delayed production of neutralizing antibodies correlates with fatal COVID-19. <i>Nature Medicine</i> 27 , 1178-1186 (2021). 10.1038/s41591-021-01355-0
531 532 533 534 535 536	10	Chen, X., Pan, Z., Yue, S., Yu, F., Zhang, J., Yang, Y., Li, R., Liu, B., Yang, X., Gao, L., Li, Z., Lin, Y., Huang, Q., Xu, L., Tang, J., Hu, L., Zhao, J., Liu, P., Zhang, G., Chen, Y., Deng, K. & Ye, L. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. <i>Signal Transduction and Targeted Therapy</i> 5 , 180 (2020). 10.1038/s41392- 020-00301-9
537 538 539 540 541 542 543	11	Trinité, B., Tarrés-Freixas, F., Rodon, J., Pradenas, E., Urrea, V., Marfil, S., Rodríguez de la Concepción, M. L., Ávila-Nieto, C., Aguilar-Gurrieri, C., Barajas, A., Ortiz, R., Paredes, R., Mateu, L., Valencia, A., Guallar, V., Ruiz, L., Grau, E., Massanella, M., Puig, J., Chamorro, A., Izquierdo-Useros, N., Segalés, J., Clotet, B., Carrillo, J., Vergara-Alert, J. & Blanco, J. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. <i>Scientific Reports</i> 11 , 2608 (2021). 10.1038/s41598-021-81862-9
544 545 546 547 548	12	Lau, E. H. Y., Tsang, O. T. Y., Hui, D. S. C., Kwan, M. Y. W., Chan, Wh., Chiu, S. S., Ko, R. L. W., Chan, K. H., Cheng, S. M. S., Perera, R. A. P. M., Cowling, B. J., Poon, L. L. M. & Peiris, M. Neutralizing antibody titres in SARS-CoV-2 infections. <i>Nature Communications</i> 12 , 63 (2021). 10.1038/s41467-020-20247-4
549 550 551 552 553 554 555 556 557 558 559	13	Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O'Byrne, A., Kouphou, N., Galao, R. P., Betancor, G., Wilson, H. D., Signell, A. W., Winstone, H., Kerridge, C., Huettner, I., Jimenez-Guardeño, J. M., Lista, M. J., Temperton, N., Snell, L. B., Bisnauthsing, K., Moore, A., Green, A., Martinez, L., Stokes, B., Honey, J., Izquierdo-Barras, A., Arbane, G., Patel, A., Tan, M. K. I., O'Connell, L., O'Hara, G., MacMahon, E., Douthwaite, S., Nebbia, G., Batra, R., Martinez-Nunez, R., Shankar-Hari, M., Edgeworth, J. D., Neil, S. J. D., Malim, M. H. & Doores, K. J. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV- 2 infection in humans. <i>Nature Microbiology</i> 5 , 1598-1607 (2020). 10.1038/s41564-020- 00813-8
560 561 562 563 564 565 566	14	Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigaill, J., Pillet, S., Grattard, F., Gonzalo, S., Verhoeven, P., Allatif, O., Berthelot, P., Pélissier, C., Thiery, G., Botelho- Nevers, E., Millet, G., Morel, J., Paul, S., Walzer, T., Cosset, FL., Bourlet, T. & Pozzetto, B. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. <i>Cellular & Molecular Immunology</i> 18 , 318-327 (2021). 10.1038/s41423-020-00588-2

perpetuit	у.
It is made available under a CC-BY-	ND 4.0 International license

567 568 569 570 571 572	15	Schlickeiser, S., Schwarz, T., Steiner, S., Wittke, K., Al Besher, N., Meyer, O., Kalus, U., Pruß, A., Kurth, F., Zoller, T., Witzenrath, M., Sander, L. E., Müller, M. A., Scheibenbogen, C., Volk, H. D., Drosten, C., Corman, V. M. & Hanitsch, L. G. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. <i>Front Immunol</i> 11 , 628971 (2020). PMC7878374. 10.3389/fimmu.2020.628971
573 574 575 576 577	16	Xu, X., Nie, S., Wang, Y., Long, Q., Zhu, H., Zhang, X., Sun, J., Zeng, Q., Zhao, J., Liu, L., Li, L., Huang, A., Hou, J. & Hou, F. F. Dynamics of neutralizing antibody responses to SARS- CoV-2 in patients with COVID-19: an observational study. <i>Signal Transduction and Targeted Therapy</i> 6 , 197 (2021). 10.1038/s41392-021-00611-6
578 579 580 581 582	17	Kim, Y., Bae, JY., Kwon, K., Chang, HH., Lee, W. K., Park, H., Kim, J., Choi, I., Park, MS. & Kim, SW. Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity. <i>Scientific Reports</i> 12 , 13491 (2022). 10.1038/s41598-022-17605-1
583 584 585 586 587 588 589 590	18	Boonyaratanakornkit, J., Morishima, C., Selke, S., Zamora, D., McGuffin, S., Shapiro, A. E., Campbell, V. L., McClurkan, C. L., Jing, L., Gross, R., Liang, J., Postnikova, E., Mazur, S., Lukin, V. V., Chaudhary, A., Das, M. K., Fink, S. L., Bryan, A., Greninger, A. L., Jerome, K. R., Holbrook, M. R., Gernsheimer, T. B., Wener, M. H., Wald, A. & Koelle, D. M. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. <i>J Clin Invest</i> 131 (2021). PMC7843229. 10.1172/jci144930
591 592 593 594 595 596 597	19	Klein, S. L., Pekosz, A., Park, H. S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K., Kumar, S., Naik, H. M., Betenbaugh, M. J., Shrestha, R., Wu, A. A., Hughes, R. M., Burgess, I., Caturegli, P., Laeyendecker, O., Quinn, T. C., Sullivan, D., Shoham, S., Redd, A. D., Bloch, E. M., Casadevall, A. & Tobian, A. A. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. <i>J Clin Invest</i> 130 , 6141-6150 (2020). PMC7598041. 10.1172/jci142004
598 599 600 601 602 603	20	Sui, Z., Dai, X., Lu, Q., Zhang, Y., Huang, M., Li, S., Peng, T., Xie, J., Zhang, Y., Wu, C., Xia, J., Dong, L., Yang, J., Huang, W., Liu, S., Wang, Z., Li, K., Yang, Q., Zhou, X., Wu, Y., Liu, W., Fang, X. & Peng, K. Viral dynamics and antibody responses in people with asymptomatic SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> 6 , 181 (2021). 10.1038/s41392-021-00596-2
604 605 606 607 608	21	Long, Q. X., Tang, X. J., Shi, Q. L., Li, Q., Deng, H. J., Yuan, J., Hu, J. L., Xu, W., Zhang, Y., Lv, F. J., Su, K., Zhang, F., Gong, J., Wu, B., Liu, X. M., Li, J. J., Qiu, J. F., Chen, J. & Huang, A. L. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. <i>Nat Med</i> 26 , 1200-1204 (2020). 10.1038/s41591-020-0965-6
609 610 611 612 613	22	Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, S. A. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. <i>Clin</i> <i>Infect Dis</i> 73 , e2005-e2015 (2021). PMC7499501. 10.1093/cid/ciaa1198

medRxiv preprint doi: https://doi.org/10.1101/2024.08.21.24312063; this version posted August 21, 2024. The copyright holder for this print in

	preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint perpetuity. It is made available under a CC-BY-ND 4.0 International license .
614 615 616 617 618 619 620 621	23	Wang, Y., Zhang, L., Sang, L., Ye, F., Ruan, S., Zhong, B., Song, T., Alshukairi, A. N., Chen, R., Zhang, Z., Gan, M., Zhu, A., Huang, Y., Luo, L., Mok, C. K. P., Al Gethamy, M. M., Tan, H., Li, Z., Huang, X., Li, F., Sun, J., Zhang, Y., Wen, L., Li, Y., Chen, Z., Zhuang, Z., Zhuo, J., Chen, C., Kuang, L., Wang, J., Lv, H., Jiang, Y., Li, M., Lin, Y., Deng, Y., Tang, L., Liang, J., Huang, J., Perlman, S., Zhong, N., Zhao, J., Malik Peiris, J. S., Li, Y. & Zhao, J. Kinetics of viral load and antibody response in relation to COVID-19 severity. <i>J Clin Invest</i> 130 , 5235- 5244 (2020). PMC7524490. 10.1172/jci138759
622 623 624	24	Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. <i>Nat Rev Microbiol</i> 20 , 270- 284 (2022). 10.1038/s41579-022-00713-0
625 626 627 628 629	25	Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F. & Moch, H. Endothelial cell infection and endotheliitis in COVID-19. <i>Lancet</i> 395 , 1417-1418 (2020). PMC7172722. 10.1016/s0140-6736(20)30937-5
630 631 632 633 634 635 636	26	Karim, F., Gazy, I., Cele, S., Zungu, Y., Krause, R., Bernstein, M., Khan, K., Ganga, Y., Rodel, H., Mthabela, N., Mazibuko, M., Muema, D., Ramjit, D., Ndung'u, T., Hanekom, W., Gosnell, B., Team, CK., Lessells, R. J., Wong, E. B., de Oliveira, T., Moosa, M. S., Lustig, G., Leslie, A., Kloverpris, H. & Sigal, A. HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. <i>Elife</i> 10 (2021). PMC8676326. 10.7554/eLife.67397
637 638 640 641 642 643 644 645 646 647	27	Bekker, L. G., Garrett, N., Goga, A., Fairall, L., Reddy, T., Yende-Zuma, N., Kassanjee, R., Collie, S., Sanne, I., Boulle, A., Seocharan, I., Engelbrecht, I., Davies, M. A., Champion, J., Chen, T., Bennett, S., Mametja, S., Semenya, M., Moultrie, H., de Oliveira, T., Lessells, R. J., Cohen, C., Jassat, W., Groome, M., Von Gottberg, A., Le Roux, E., Khuto, K., Barouch, D., Mahomed, H., Wolmarans, M., Rousseau, P., Bradshaw, D., Mulder, M., Opie, J., Louw, V., Jacobson, B., Rowji, P., Peter, J. G., Takalani, A., Odhiambo, J., Mayat, F., Takuva, S., Corey, L. & Gray, G. E. Effectiveness of the Ad26.COV2.S vaccine in health- care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. <i>Lancet</i> 399 , 1141-1153 (2022). PMC8930006. 10.1016/s0140-6736(22)00007-1
648 649 650 651 652 653 654 655 656	28	Rubio-Rivas, M., Mora-Luján, J. M., Formiga, F., Arévalo-Cañas, C., Lebrón Ramos, J. M., Villalba García, M. V., Fonseca Aizpuru, E. M., Díez-Manglano, J., Arnalich Fernández, F., Romero Cabrera, J. L., García García, G. M., Pesqueira Fontan, P. M., Vargas Núñez, J. A., Freire Castro, S. J., Loureiro Amigo, J., Pascual Pérez, M. L. R., Alcalá Pedrajas, J. N., Encinas-Sánchez, D., Mella Pérez, C., Ena, J., Gracia Gutiérrez, A., Esteban Giner, M. J., Varona, J. F., Millán Núñez-Cortés, J. & Casas-Rojo, J. M. WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. <i>J Gen Intern Med</i> 37 , 1980-1987 (2022). PMC8992782. 10.1007/s11606-022-07511-7

658 29 Cele, S., Karim, F., Lustig, G., San, J. E., Hermanus, T., Tegally, H., Snyman, J., Moyo-659 Gwete, T., Wilkinson, E., Bernstein, M., Khan, K., Hwa, S. H., Tilles, S. W., Singh, L., Giandhari, J., Mthabela, N., Mazibuko, M., Ganga, Y., Gosnell, B. I., Karim, S. S. A., 660 Hanekom, W., Van Voorhis, W. C., Ndung'u, T., Team, C.-K., Lessells, R. J., Moore, P. L., 661

perpetuity.	
It is made available under a CC-BY-ND 4.0	International license.

662 663 664		Moosa, M. S., de Oliveira, T. & Sigal, A. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host Microbe</i> 30 , 154-162 e155 (2022). PMC8758318. 10.1016/j.chom.2022.01.005
665 666 667 668 669 670 671 672 673 674 675 676	30 31	 Karim, F., Moosa, M. Y., Gosnell, B., Sandile, C., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E., San, E. J. & Msomi, N. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. <i>medRxiv</i> (2021). Karim, F., Riou, C., Bernstein, M., Jule, Z., Lustig, G., van Graan, S., Keeton, R. S., Upton, JL., Ganga, Y., Khan, K., Reedoy, K., Mazibuko, M., Govender, K., Thambu, K., Ngcobo, N., Venter, E., Makhado, Z., Hanekom, W., von Gottberg, A., Hoque, M., Karim, Q. A., Abdool Karim, S. S., Manickchund, N., Magula, N., Gosnell, B. I., Lessells, R. J., Moore, P. L., Burgers, W. A., de Oliveira, T., Moosa, MY. S. & Sigal, A. Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation. <i>Nature Communications</i> 15, 2360 (2024). 10.1038/s41467-024-46673-2
677 678 679 680 681 682 683	32	Cele, S., Gazy, I., Jackson, L., Hwa, S. H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell, B. I., Hanekom, W., Moosa, M. S., Network for Genomic Surveillance in South, A., Team, CK., Lessells, R. J., de Oliveira, T. & Sigal, A. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. <i>Nature</i> 593 , 142-146 (2021). PMC9867906. 10.1038/s41586-021-03471-w
684 685 686 687 688 689 690 691	33	Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D. G., Karim, F., Bernstein, M., Lustig, G., Archary, D., Smith, M., Ganga, Y., Jule, Z., Reedoy, K., Hwa, S. H., Giandhari, J., Blackburn, J. M., Gosnell, B. I., Abdool Karim, S. S., Hanekom, W., Ngs, S. A., Team, CK., von Gottberg, A., Bhiman, J. N., Lessells, R. J., Moosa, M. S., Davenport, M. P., de Oliveira, T., Moore, P. L. & Sigal, A. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> 602 , 654-656 (2022). PMC8866126. 10.1038/s41586-021-04387-1
692 693 694 695 696 697	34	Kharsany, A. B. M., Cawood, C., Khanyile, D., Lewis, L., Grobler, A., Puren, A., Govender, K., George, G., Beckett, S., Samsunder, N., Madurai, S., Toledo, C., Chipeta, Z., Glenshaw, M., Hersey, S. & Abdool Karim, Q. Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. <i>Lancet HIV</i> 5 , e427-e437 (2018). PMC7498647. 10.1016/S2352-3018(18)30104-8
698 699 700 701 702	35	Shouman, S., El-Kholy, N., Hussien, A. E., El-Derby, A. M., Magdy, S., Abou-Shanab, A. M., Elmehrath, A. O., Abdelwaly, A., Helal, M. & El-Badri, N. SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147. <i>Cell Communication and Signaling</i> 22 , 349 (2024). 10.1186/s12964-024-01718-3
703 704 705 706 707	36	Zou, Zy., Ren, D., Chen, Rl., Yu, Bj., Liu, Y., Huang, Jj., Yang, Zj., Zhou, Zp., Feng, Yw. & Wu, M. Persistent lymphopenia after diagnosis of COVID-19 predicts acute respiratory distress syndrome: A retrospective cohort study. <i>European Journal of</i> <i>Inflammation</i> 19 , 20587392211036825 (2021). 10.1177/20587392211036825

709 710 711 712	37	Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W. & Tian, DS. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. <i>Clinical Infectious Diseases</i> 71 , 762-768 (2020). 10.1093/cid/ciaa248
713 714 715 716 717	38	Li, X., Liu, C., Mao, Z., Xiao, M., Wang, L., Qi, S. & Zhou, F. Predictive values of neutrophil- to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. <i>Crit Care</i> 24 , 647 (2020). PMC7667659. 10.1186/s13054-020-03374-8
718 719 720 721 722	39	Prebensen, C., Lefol, Y., Myhre, P. L., Lüders, T., Jonassen, C., Blomfeldt, A., Omland, T., Nilsen, H. & Berdal, JE. Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19. <i>Scientific Reports</i> 13 , 10368 (2023). 10.1038/s41598-023-37606-y
723 724 725 726 727 728	40	Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Raffler, J., Kerrison, N. D., Oerton, E., Auyeung, V. P. W., Luan, J. a., Finan, C., Casas, J. P., Ostroff, R., Williams, S. A., Kastenmüller, G., Ralser, M., Gamazon, E. R., Wareham, N. J., Hingorani, A. D. & Langenberg, C. Genetic architecture of host proteins involved in SARS-CoV-2 infection. <i>Nature Communications</i> 11 , 6397 (2020). 10.1038/s41467-020-19996-z
729 730 731 732 733	41	Yang, J., Chen, C., Chen, W., Huang, L., Fu, Z., Ye, K., Lv, L., Nong, Z., Zhou, X., Lu, W. & Zhong, M. Proteomics and metabonomics analyses of Covid-19 complications in patients with pulmonary fibrosis. <i>Scientific Reports</i> 11 , 14601 (2021). 10.1038/s41598-021-94256-8
734 735 736 737 738 739	42	Dunn, J., Ferluga, S., Sharma, V., Futschik, M., Hilton, D. A., Adams, C. L., Lasonder, E. & Hanemann, C. O. Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. <i>EBioMedicine</i> 40 , 77-91 (2019). PMC6412084. 10.1016/j.ebiom.2018.12.048
740 741 742 743 744 745 746	43	Liu, W., Xie, L., He, YH., Wu, ZY., Liu, LX., Bai, XF., Deng, DX., Xu, XE., Liao, LD., Lin, W., Heng, JH., Xu, X., Peng, L., Huang, QF., Li, CY., Zhang, ZD., Wang, W., Zhang, GR., Gao, X., Wang, SH., Li, CQ., Xu, LY., Liu, W. & Li, EM. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. <i>Nature Communications</i> 12 , 4961 (2021). 10.1038/s41467-021-25202-5
747 748 749	44	Stricher, F., Macri, C., Ruff, M. & Muller, S. HSPA8/HSC70 chaperone protein. <i>Autophagy</i> 9 , 1937-1954 (2013). 10.4161/auto.26448
750 751 752 753	45	Chappell, T. G., Welch, W. J., Schlossman, D. M., Palter, K. B., Schlesinger, M. J. & Rothman, J. E. Uncoating ATPase is a member of the 70 kilodalton family of stress proteins. <i>Cell</i> 45 , 3-13 (1986). 10.1016/0092-8674(86)90532-5
754		

755 756 757	46	Panjwani, N., Akbari, O., Garcia, S., Brazil, M. & Stockinger, B. The HSC73 Molecular Chaperone: Involvement in MHC Class II Antigen Presentation. <i>The Journal of</i> <i>Immunology</i> 163 , 1936-1942 (1999). 10.4049/jimmunol.163.4.1936
758 759 760 761 762	47	Navhaya, L. T., Blessing, D. M., Yamkela, M., Godlo, S. & Makhoba, X. H. A comprehensive review of the interaction between COVID-19 spike proteins with mammalian small and major heat shock proteins. <i>Biomolecular Concepts</i> 15 (2024). doi:10.1515/bmc-2022-0027
763 764 765 766 767	48	Watanabe, K., Fuse, T., Asano, I., Tsukahara, F., Maru, Y., Nagata, K., Kitazato, K. & Kobayashi, N. Identification of Hsc70 as an influenza virus matrix protein (M1) binding factor involved in the virus life cycle. <i>FEBS Lett</i> 580 , 5785-5790 (2006). 10.1016/j.febslet.2006.09.040
768 769 770 771	49	Florin, L., Becker, K. A., Sapp, C., Lambert, C., Sirma, H., Müller, M., Streeck, R. E. & Sapp, M. Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. <i>J Virol</i> 78 , 5546-5553 (2004). PMC415841. 10.1128/jvi.78.11.5546-5553.2004
772 773 774 775 776 777 778 779	50	Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J. K., Zhang, L., Bopp, N., Schindewolf, C., Vu, M., Vanderheiden, A., Winkler, E. S., Swetnam, D., Plante, J. A., Aguilar, P., Plante, K. S., Popov, V., Lee, B., Weaver, S. C., Suthar, M. S., Routh, A. L., Ren, P., Ku, Z., An, Z., Debbink, K., Diamond, M. S., Shi, P. Y., Freiberg, A. N. & Menachery, V. D. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. <i>Nature</i> 591 , 293-299 (2021). PMC8175039. 10.1038/s41586-021-03237-4
780 781 782 783	51	Zeng, Q., Antia, A., Casorla-Perez, L. A., Puray-Chavez, M., Kutluay, S. B., Ciorba, M. A. & Ding, S. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels. <i>mBio</i> 15 , e02287-02223 (2024). doi:10.1128/mbio.02287-23
784 785 786 787 788	52	Shiokawa, D., Matsushita, T., Kobayashi, T., Matsumoto, Y. & Tanuma, Si. Characterization of the human DNAS1L2 gene and the molecular mechanism for its transcriptional activation induced by inflammatory cytokines. <i>Genomics</i> 84 , 95-105 (2004)
789 790 791	53	Anelli, T., Alessio, M., Mezghrani, A., Simmen, T., Talamo, F., Bachi, A. & Sitia, R. ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family. <i>The EMBO Journal</i> 21 , 835-844 (2002). <u>https://doi.org/10.1093/emboj/21.4.835</u>
792 793 794 795 796	54	Liu, P., Wang, X., Sun, Y., Zhao, H., Cheng, F., Wang, J., Yang, F., Hu, J., Zhang, H., Wang, Cc. & Wang, L. SARS-CoV-2 ORF8 reshapes the ER through forming mixed disulfides with ER oxidoreductases. <i>Redox Biology</i> 54 , 102388 (2022). https://doi.org/10.1016/j.redox.2022.102388
797 798 799 800	55	Sun, J. & Jacquez, P. Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane Insertion and Pore Formation. <i>Toxins (Basel)</i> 8 , 34 (2016). PMC4773787. 10.3390/toxins8020034

	perpetuity.		
It is made available under a	CC-BY-ND 4.0) International	license.

801 802 803 804 805	56	Needham, B. E., Wlodek, M. E., Ciccotosto, G. D., Fam, B. C., Masters, C. L., Proietto, J., Andrikopoulos, S. & Cappai, R. Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. <i>J Pathol</i> 215 , 155-163 (2008). 10.1002/path.2343
806 807 808 809 810	57	Chen, J., Chen, J., Lei, Z., Zhang, F., Zeng, L. H., Wu, X., Li, S. & Tan, J. Amyloid precursor protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid-β-associated pathology in APP/PS1 mouse model of Alzheimer's disease. <i>Transl Psychiatry</i> 13 , 396 (2023). PMC10725492. 10.1038/s41398-023-02692-z
811 812 813 814 815 816 817 818 819 820	58 59 60	 Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R. & Lander, E. S. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. <i>Proceedings of the National Academy of Sciences</i> 102, 15545-15550 (2005). Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P. & Tamayo, P. The molecular signatures database hallmark gene set collection. <i>Cell systems</i> 1, 417-425 (2015). Fitzgerald, A. A. & Weiner, L. M. The role of fibroblast activation protein in health and malignancy. <i>Cancer Metastasis Rev</i> 39, 783-803 (2020). PMC7487063. 10.1007/s10555-
821 822 823 824 825	61	020-09909-3 Deloose, E., Verbeure, W., Depoortere, I. & Tack, J. Motilin: from gastric motility stimulation to hunger signalling. <i>Nature Reviews Endocrinology</i> 15 , 238-250 (2019). 10.1038/s41574-019-0155-0
826 827 828 829 830 831	62	Tsai, H. Y., Yang, Y. F., Wu, A. T., Yang, C. J., Liu, Y. P., Jan, Y. H., Lee, C. H., Hsiao, Y. W., Yeh, C. T., Shen, C. N., Lu, P. J., Huang, M. S. & Hsiao, M. Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. <i>Oncogene</i> 32 , 4921-4931 (2013). 10.1038/onc.2012.514
832 833 834 835 836 837	63	McClain, M. T., Constantine, F. J., Henao, R., Liu, Y., Tsalik, E. L., Burke, T. W., Steinbrink, J. M., Petzold, E., Nicholson, B. P., Rolfe, R., Kraft, B. D., Kelly, M. S., Saban, D. R., Yu, C., Shen, X., Ko, E. M., Sempowski, G. D., Denny, T. N., Ginsburg, G. S. & Woods, C. W. Dysregulated transcriptional responses to SARS-CoV-2 in the periphery. <i>Nature Communications</i> 12 , 1079 (2021). 10.1038/s41467-021-21289-y
838 839 840 841 842 843	64	González-García, I., Freire-Agulleiro, Ó., Nakaya, N., Ortega, F. J., Garrido-Gil, P., Liñares-Pose, L., Fernø, J., Labandeira-Garcia, J. L., Diéguez, C., Sultana, A., Tomarev, S. I., Fernández-Real, J. M. & López, M. Olfactomedin 2 deficiency protects against diet- induced obesity. <i>Metabolism</i> 129 , 155122 (2022). <u>https://doi.org/10.1016/j.metabol.2021.155122</u>
844 845 846 847	65	Kim, YM. & Shin, EC. Type I and III interferon responses in SARS-CoV-2 infection. <i>Experimental & Molecular Medicine</i> 53 , 750-760 (2021). 10.1038/s12276-021-00592-0
UT/		

848 849 850 851 852 853	66	Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., Kulke, M. H., Baird, R. D., Prabhu, J. S., Carbone, D., Pecoraro, C., Teh, D. B. L., Sethi, G., Cavalieri, V., Lin, K. H., Javidi-Sharifi, N. R., Toska, E., Davids, M. S., Brown, J. R., Diana, P., Stebbing, J., Fruman, D. A. & Kumar, A. P. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. <i>Molecular Cancer</i> 22 , 138 (2023). 10.1186/s12943-023-01827-6
854 855 856 857	67	Fattahi, S., Khalifehzadeh-Esfahani, Z., Mohammad-Rezaei, M., Mafi, S. & Jafarinia, M. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy. <i>Immunol Res</i> 70 , 269-275 (2022). PMC8808470. 10.1007/s12026-022-09268-x
858 859 860 861 862	68	Basile, M. S., Cavalli, E., McCubrey, J., Hernández-Bello, J., Muñoz-Valle, J. F., Fagone, P. & Nicoletti, F. The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. <i>Drug Discovery Today</i> 27 , 848-856 (2022). https://doi.org/10.1016/j.drudis.2021.11.002
863 864 865 866	69	Abu-Eid, R. & Ward, F. J. Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients. <i>Immunology Letters</i> 240 , 1-8 (2021). https://doi.org/10.1016/j.imlet.2021.09.005
867 868 869 870 871	70	Shin, H. J., Lee, W., Ku, K. B., Yoon, G. Y., Moon, HW., Kim, C., Kim, MH., Yi, YS., Jun, S., Kim, BT., Oh, JW., Siddiqui, A. & Kim, SJ. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation. <i>Signal Transduction and Targeted Therapy</i> 9 , 125 (2024). 10.1038/s41392-024-01836-x
872 873 874 875	71	Ben-Sahra, I. & Manning, B. D. mTORC1 signaling and the metabolic control of cell growth. <i>Current Opinion in Cell Biology</i> 45 , 72-82 (2017). https://doi.org/10.1016/j.ceb.2017.02.012
876 877 878 879 880 881	72	Mullen, P. J., Garcia, G., Purkayastha, A., Matulionis, N., Schmid, E. W., Momcilovic, M., Sen, C., Langerman, J., Ramaiah, A., Shackelford, D. B., Damoiseaux, R., French, S. W., Plath, K., Gomperts, B. N., Arumugaswami, V. & Christofk, H. R. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. <i>Nature Communications</i> 12 , 1876 (2021). 10.1038/s41467-021-22166-4
882 883 884 885	73	Zhou, Y., Huang, J., Jin, B., He, S., Dang, Y., Zhao, T. & Jin, Z. The Emerging Role of Hedgehog Signaling in Viral Infections. <i>Front Microbiol</i> 13 , 870316 (2022). PMC9023792. 10.3389/fmicb.2022.870316
886 887 888 888	74	Abu-Farha, M., Thanaraj, T. A., Qaddoumi, M. G., Hashem, A., Abubaker, J. & Al-Mulla, F. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. <i>Int J Mol</i> <i>Sci</i> 21 (2020). PMC7278986. 10.3390/ijms21103544
890 891 892	75	D'Avila, H., Lima, C. N. R., Rampinelli, P. G., Mateus, L. C. O., Sousa Silva, R. V. d., Correa, J. R. & Almeida, P. E. d. Lipid Metabolism Modulation during SARS-CoV-2

893 894 895 896 897 898	76	Infection: A Spotlight on Extracellular Vesicles and Therapeutic Prospects. <i>International Journal of Molecular Sciences</i> 25 , 640 (2024). Chu, J., Xing, C., Du, Y., Duan, T., Liu, S., Zhang, P., Cheng, C., Henley, J., Liu, X., Qian, C., Yin, B., Wang, H. Y. & Wang, RF. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. <i>Nature Metabolism</i> 3 , 1466-1475 (2021). 10.1038/s42255-021-00479-4
899 900 901 902 903	77	Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O'Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F. & Horwitz, L. I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. <i>Bmj</i> 369 , m1966 (2020). PMC7243801. 10.1136/bmj.m1966
904 905 906 907 908 909	78	Tartof, S. Y., Qian, L., Hong, V., Wei, R., Nadjafi, R. F., Fischer, H., Li, Z., Shaw, S. F., Caparosa, S. L., Nau, C. L., Saxena, T., Rieg, G. K., Ackerson, B. K., Sharp, A. L., Skarbinski, J., Naik, T. K. & Murali, S. B. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. <i>Ann Intern Med</i> 173 , 773-781 (2020). PMC7429998. 10.7326/m20-3742
910 911 912 913 914	79	Moriconi, D., Masi, S., Rebelos, E., Virdis, A., Manca, M. L., De Marco, S., Taddei, S. & Nannipieri, M. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. <i>Obes Res Clin Pract</i> 14 , 205-209 (2020). PMC7269944. 10.1016/j.orcp.2020.05.009
915 916 917 918 919 920 921	80	Martínez-Colón, G. J., Ratnasiri, K., Chen, H., Jiang, S., Zanley, E., Rustagi, A., Verma, R., Chen, H., Andrews, J. R., Mertz, K. D., Tzankov, A., Azagury, D., Boyd, J., Nolan, G. P., Schürch, C. M., Matter, M. S., Blish, C. A. & McLaughlin, T. L. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. <i>Science Translational Medicine</i> 14 , eabm9151 (2022). doi:10.1126/scitranslmed.abm9151
922 923 924 925	81	Johnson, C. H., Patterson, A. D., Idle, J. R. & Gonzalez, F. J. Xenobiotic metabolomics: major impact on the metabolome. <i>Annu Rev Pharmacol Toxicol</i> 52 , 37-56 (2012). PMC6300990. 10.1146/annurev-pharmtox-010611-134748
926 927 928 929 930 931 932 933 934 935 936 936	82	Codo, A. C., Davanzo, G. G., Monteiro, L. B., de Souza, G. F., Muraro, S. P., Virgilio-da- Silva, J. V., Prodonoff, J. S., Carregari, V. C., de Biagi Junior, C. A. O., Crunfli, F., Jimenez Restrepo, J. L., Vendramini, P. H., Reis-de-Oliveira, G., Bispo Dos Santos, K., Toledo- Teixeira, D. A., Parise, P. L., Martini, M. C., Marques, R. E., Carmo, H. R., Borin, A., Coimbra, L. D., Boldrini, V. O., Brunetti, N. S., Vieira, A. S., Mansour, E., Ulaf, R. G., Bernardes, A. F., Nunes, T. A., Ribeiro, L. C., Palma, A. C., Agrela, M. V., Moretti, M. L., Sposito, A. C., Pereira, F. B., Velloso, L. A., Vinolo, M. A. R., Damasio, A., Proença- Módena, J. L., Carvalho, R. F., Mori, M. A., Martins-de-Souza, D., Nakaya, H. I., Farias, A. S. & Moraes-Vieira, P. M. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. <i>Cell Metab</i> 32 , 437- 446.e435 (2020). PMC7367032. 10.1016/j.cmet.2020.07.007

939 940	83	Sanchez, E. L. & Lagunoff, M. Viral activation of cellular metabolism. <i>Virology</i> 479-480 , 609-618 (2015). PMC4424078. 10.1016/j.virol.2015.02.038
941 942 943 944	84	Chen, P., Wu, M., He, Y., Jiang, B. & He, ML. Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection. <i>Signal Transduction and Targeted Therapy</i> 8 , 237 (2023). 10.1038/s41392-023-01510-8
945 946 947	85	Kierans, S. J. & Taylor, C. T. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. <i>J Physiol</i> 599 , 23-37 (2021). 10.1113/jp280572
948 949 950 951 952 953 954 955 956	86 87	 Keramidas, P., Pitou, M., Papachristou, E. & Choli-Papadopoulou, T. Insights into the Activation of Unfolded Protein Response Mechanism during Coronavirus Infection. <i>Current Issues in Molecular Biology</i> 46, 4286-4308 (2024). Barrera, M. J., Aguilera, S., Castro, I., González, S., Carvajal, P., Molina, C., Hermoso, M. A. & González, M. J. Endoplasmic reticulum stress in autoimmune diseases: Can altered protein quality control and/or unfolded protein response contribute to autoimmunity? A critical review on Sjögren's syndrome. <i>Autoimmun Rev</i> 17, 796-808 (2018). 10.1016/j.autrev.2018.02.009
957 958 959	88	Sharma, C. & Bayry, J. High risk of autoimmune diseases after COVID-19. <i>Nature Reviews Rheumatology</i> 19 , 399-400 (2023). 10.1038/s41584-023-00964-y
960 961 962 963 964	89	Sui, L., Li, L., Zhao, Y., Zhao, Y., Hao, P., Guo, X., Wang, W., Wang, G., Li, C. & Liu, Q. Host cell cycle checkpoint as antiviral target for SARS-CoV-2 revealed by integrative transcriptome and proteome analyses. <i>Signal Transduction and Targeted Therapy</i> 8 , 21 (2023). 10.1038/s41392-022-01296-1
965 966 967 968	90	Wisdom, R., Johnson, R. S. & Moore, C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. <i>The EMBO Journal</i> 18 , 188-197 (1999). https://doi.org/10.1093/emboj/18.1.188
969 970 971 972 973	91	Li, H., Xiao, X., Zhang, J., Zafar, M. I., Wu, C., Long, Y., Lu, W., Pan, F., Meng, T., Zhao, K., Zhou, L., Shen, S., Liu, L., Liu, Q. & Xiong, C. Impaired spermatogenesis in COVID-19 patients. <i>EClinicalMedicine</i> 28 , 100604 (2020). PMC7584442. 10.1016/j.eclinm.2020.100604
974 975 976 977 978 979	92	Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J., Ehmann, R., Zwirglmaier, K., Drosten, C. & Wendtner, C. Virological assessment of hospitalized patients with COVID-2019. <i>Nature</i> 581 , 465-469 (2020). 10.1038/s41586-020-2196-x
980 981 982	93	Sousa, R. & Lafer, E. M. The role of molecular chaperones in clathrin mediated vesicular trafficking. <i>Front Mol Biosci</i> 2 , 26 (2015). PMC4436892. 10.3389/fmolb.2015.00026

984 985 986	94	Bayati, A., Kumar, R., Francis, V. & McPherson, P. S. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. <i>J Biol Chem</i> 296 , 100306 (2021). PMC7816624. 10.1016/j.jbc.2021.100306
987 988 989	95	Lanzavecchia, A. Antigen-specific interaction between T and B cells. <i>Nature</i> 314 , 537- 539 (1985).
990 991 992 993 994	96	van den Berg, J., Haslbauer, J. D., Stalder, A. K., Romanens, A., Mertz, K. D., Studt, JD., Siegemund, M., Buser, A., Holbro, A. & Tzankov, A. Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies. <i>Research and</i> <i>Practice in Thrombosis and Haemostasis</i> 7 , 100182 (2023). https://doi.org/10.1016/j.rpth.2023.100182
995 996 997 998 999 1000 1001 1002	97	Fitzek, A., Schädler, J., Dietz, E., Ron, A., Gerling, M., Kammal, A. L., Lohner, L., Falck, C., Möbius, D., Goebels, H., Gerberding, AL., Schröder, A. S., Sperhake, JP., Klein, A., Fröb, D., Mushumba, H., Wilmes, S., Anders, S., Kniep, I., Heinrich, F., Langenwalder, F., Meißner, K., Lange, P., Zapf, A., Püschel, K., Heinemann, A., Glatzel, M., Matschke, J., Aepfelbacher, M., Lütgehetmann, M., Steurer, S., Thorns, C., Edler, C. & Ondruschka, B. Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases. <i>Scientific Reports</i> 11 , 19342 (2021). 10.1038/s41598-021-98499-3
1003 1004 1005 1006 1007 1008	98	Elezkurtaj, S., Greuel, S., Ihlow, J., Michaelis, E. G., Bischoff, P., Kunze, C. A., Sinn, B. V., Gerhold, M., Hauptmann, K., Ingold-Heppner, B., Miller, F., Herbst, H., Corman, V. M., Martin, H., Radbruch, H., Heppner, F. L. & Horst, D. Causes of death and comorbidities in hospitalized patients with COVID-19. <i>Scientific Reports</i> 11 , 4263 (2021). 10.1038/s41598-021-82862-5
1009 1010 1011 1012 1013 1014 1015	99 100	Kraemer, S., Vaught, J. D., Bock, C., Gold, L., Katilius, E., Keeney, T. R., Kim, N., Saccomano, N. A., Wilcox, S. K. & Zichi, D. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. <i>PloS one</i> 6 , e26332 (2011). Storey, J. D. A direct approach to false discovery rates. <i>Journal of the Royal Statistical</i> <i>Society: Series B (Statistical Methodology)</i> 64 , 479-498 (2002).
1016		https://doi.org/10.1111/1467-9868.00346
1017 1018 1019 1020 1021 1022 1023	101	Mootha, V. K., Lindgren, C. M., Eriksson, KF., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., Houstis, N., Daly, M. J., Patterson, N., Mesirov, J. P., Golub, T. R., Tamayo, P., Spiegelman, B., Lander, E. S., Hirschhorn, J. N., Altshuler, D. & Groop, L. C. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. <i>Nature</i> <i>Genetics</i> 34 , 267-273 (2003). 10.1038/ng1180
1024		
1025		
1026		

1027 Figure legends

1028

Figure 1: Study design and timeline. Study participants were enrolled in the first South African SARS-CoV-2 infection wave between March and October 2020, where enrollment was a median of 6 days post-diagnosis. At enrollment, disease severity was assessed by whether a participant required supplemental oxygen. During this visit, a blood draw was performed, and blood plasma used for proteomic analysis using SomaScan proteomics. At 28 days postenrollment, a second blood draw was performed, and blood plasma was used in a live virus neutralization assay against ancestral SARS-CoV-2 to assess neutralization capacity.

1036

1037 Figure 2: Neutralization capacity associates with disease severity but not HIV status. 1038 (A) Participants were divided into high and low neutralizers based on whether the participant's plasma showed higher or lower neutralizing capacity relative to the median neutralization 1039 1040 FRNT₅₀ of all participants. For all plots, y-axis shows FRNT₅₀, with bar and error bars 1041 representing the geometric mean and geometric standard deviation of each group. The horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma 1042 1043 concentration used). (B) Participants in the high and low neutralization groups who required 1044 supplemental oxygen (red points). Inset shows frequency of participants on supplemental 1045 oxygen in each group (p=0.0046 by Fisher's exact test). (C) High and low neutralizers who had a neutrophil to lymphocyte ratio (NLR) greater than 6. Inset: frequency of high NLR in 1046 1047 each group (p=0.011 by Fisher's exact test). (D) High and low neutralizers who had a comorbidity of diabetes, hypertension, or both. Inset: frequency of comorbidities in each group 1048 1049 (p=0.00018 by Fisher's exact test). (E) High and low neutralizers who were male. Inset: frequency of males in each group (p=0.042 by Fisher's exact test). (F) High and low 1050 neutralizers who were people living with HIV (PLWH). Inset: frequency of PLWH in each group 1051 1052 (not significant by Fisher's exact test). (G) Univariate and (H) multivariate logistic regression 1053 odds ratios for odds of having a high neutralization response.

1054

1055 Figure 3: Differentially expressed proteins in neutralization and disease severity. Volcano plots show fold-change versus false discovery rate (FDR) values for each protein in 1056 two comparisons: (A) High neutralizers compared to low neutralizers; (B) severe versus non-1057 severe disease. The x-axis represents the log fold-change between the mean protein level 1058 values in the group of high versus low neutralizers or high versus low disease severity. Y-axis 1059 is the $-\log_{10}$ transformed FDR. The vertical lines indicate ±1.5-fold change and the horizontal 1060 1061 line FDR=0.05. Significantly differentially expressed proteins are labeled in red (upregulated), blue (downregulated), and green (shared between responses). (C) Venn diagram showing the 1062 1063 number of differentially expressed proteins associated with neutralization capacity and 1064 disease severity and common to both.

1065

1066 Figure 4. Significantly regulated pathways for neutralization and disease severity. Gene Set Enrichment Analysis (GSEA) results for significantly up or downregulated pathways in 1067 1068 participants with high neutralization versus low capacity and those with severe versus nonsevere disease. The x-axis represents the Normalized Enrichment Score (NES). Each circle 1069 1070 represents a pathway, with the size of the circle corresponding to the -log₁₀(FDR) value, with 1071 larger circles indicating higher significance. Purple circles represent pathways enriched in the high neutralization group and orange circles represent pathways enriched in the severe 1072 1073 disease group. One pathway (fatty acid metabolism) is shared between both groups.

1075 Figure 5: Top differentially expressed proteins in the neutralization response show 1076 similar expression in high neutralizers regardless of disease severity. Median Z-score 1077 normalized protein levels of the top 20 differentially expressed proteins by FDR are shown for the high neutralizers with severe disease, high neutralizers with non-severe disease, and low 1078 1079 neutralizers. Fourteen out of the 20 proteins (left) show no significant difference between the 1080 high neutralizers with severe disease versus high neutralizers with non-severe disease. Six proteins (right) show significantly higher levels in high neutralizers with severe disease relative 1081 1082 to high neutralizers with non-severe disease. However, the levels of these proteins in low neutralizers are significantly lower still. P-values by the Kruskal-Wallis test with multiple 1083 1084 hypothesis correction between group values per protein.

1085

1086 Figure 6: Predictive models classifying participants into high versus low neutralization groups. Shown are ROC curves for (A) multivariate (HSPA8+FAP+MLN), (B) HSPA8, (C) FAP, 1087 and (D) MLN. Areas Under the Curve (AUC) were 0.91 (multivariate). 0.86 (HSP8A). 0.84 1088 (FAP), and 0.79 (MLN). Dashed diagonal line represents the performance of a random 1089 1090 classifier with AUC=0.50.

1091

1092 Figure 7: Top differentially expressed proteins in the disease severity response show 1093 similar expression regardless of neutralization capacity. Median Z-score normalized protein of the top 20 differentially expressed proteins by FDR are shown for the high severity 1094 1095 group and the low severity group, with the latter divided into high and low neutralizers. Sixteen 1096 out of the 20 proteins (left) show no significant difference between non-severe high versus low 1097 neutralizers. Three proteins (middle-right) show levels in the low severity, high neutralizer group which are intermediate between participants with high severity and low severity and low 1098 1099 neutralization. Levels of the remaining one protein show no significant difference between 1100 participants with severe disease and high neutralizers with non-severe disease. p-values by 1101 the Kruskal-Wallis test with multiple hypothesis correction between group values per protein.

1102

1103 Figure S1: Comparison of neutralization capacity of high neutralizers with low severity to participants with high disease severity. The y-axis shows FRNT₅₀, with bar and error 1104 1105 bars representing the geometric mean and geometric standard deviation of each group. The horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma 1106 1107 concentration used). p-value by the non-parametric Mann-Whitney test.

1108

Figure S2: Overlap of comorbidities and requirement for supplemental oxygen in high 1109 1110 versus low neutralizers. Participants not requiring supplemental oxygen and having neither diabetes nor hypertension are marked in blue, those requiring supplemental oxygen but 1111 1112 without diabetes or hypertension are in red, participants with diabetes or hypertension comorbidities only are in yellow, and those requiring both supplemental oxygen and with 1113 diabetes or hypertension comorbidities are in green. Inset shows relative frequencies of the 1114 1115 four groups in high versus low neutralizers.

1116

Figure S3: Significantly differentially expressed proteins in the training set. Volcano 1117 1118 plots show fold change versus false discovery rate (FDR) values for each protein. The x-axis 1119 represents the log fold-change between the mean protein level values in the group of high

1120 versus low neutralizers or high versus low disease severity. Y-axis is the $-\log_{10}$ transformed 1121 FDR. The vertical lines indicate ±1.5-fold change and the horizontal line FDR=0.05. 1122 Significantly differentially expressed proteins are labeled in red (upregulated) or blue 1123 (downregulated). The proteins showing highest predictive value in the model are highlighted

1124 in purple.



Figure 1: Study design and timeline. Study participants were enrolled in the first South African SARS-CoV-2 infection wave between March and October 2020, where enrollment was a median of 6 days post-diagnosis. At enrollment, disease severity was assessed by whether a participant required supplemental oxygen. During this visit, a blood draw was performed, and blood plasma used for proteomic analysis using SomaScan proteomics. At 32 days post-diagnosis, a second blood draw was performed, and blood plasma was used in a live virus neutralization assay against ancestral SARS-CoV-2 to assess neutralization capacity.

Table 1: Participant characteristics and comparison of non-severe vs severe groups.

Parameter	All	Non-severe	Severe	p-value
n	72	55	17	
Days diag. to enrol., median (IQR)	6(4 - 8)	6(4 - 8)	6(5-7)	0.87
Days diag. to neut. sample, median (IQR)	32(17 - 35)	30(16 - 35)	33(28 - 34)	0.22
Age in years, median (IQR)	42(34 - 50)	42(32 - 50)	40(36-55)	0.31
People living with HIV, n (%)	34(47)	25 (45)	9(53)	0.78
Sex, male $(\%)$	22(31)	15(27)	7(41)	0.37
CD4 at enrol., median (IQR)	590(340 - 940)	700 (470 - 1100)	380(270 - 590)	0.0072
CD4 at neut. sample, median (IQR)	830 (510 - 1100)	820 (530 - 1100)	840 (390 - 900)	0.43
NLR at enrol., median (IQR)	2(1.2 - 4.1)	1.9(1.2 - 2.5)	4.2(1.3 - 7.5)	0.043
NLR at neut. sample, median (IQR)	1.6 (1.2 - 2.1)	1.6 (1.2 - 2.1)	1.5 (1.2 - 1.9)	0.77
D614G FRNT ₅₀ , geomean	230	150	900	0.00052

	Non-severe	Severe	Sum
Low neutralization	33	3	36
High neutralization	22	13	35
Sum	55	16	71

 Table 2: Participant numbers in neutralization-severity combinations.



Figure 2: Neutralization capacity associates with disease severity but not HIV status. (A) Participants were divided into high and low neutralizers based on whether the participant's plasma showed higher or lower neutralizing capacity relative to the median neutralization $FRNT_{50}$ of all participants. For all plots, y-axis shows $FRNT_{50}$, with bar and error bars representing the geometric mean and geometric standard deviation of each group. The horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma concentration used). (B) Participants in the high and low neutralization groups who required supplemental oxygen (red points). Inset shows frequency of participants on supplemental oxygen in each group (p=0.0046 by Fisher's exact test). (C) High and low neutralizers who had a neutrophil to lymphocyte ratio (NLR) greater than 6. Inset: frequency of high NLR in each group (p=0.011 by Fisher's exact test). (D) High and low neutralizers who had a comorbidity of diabetes, hypertension, or both. Inset: frequency of comorbidities in each group (p=0.0018 by Fisher's exact test). (E) High and low neutralizers who were male. Inset: frequency of males in each group (p=0.042 by Fisher's exact test). (F) High and low neutralizers who were people living with HIV (PLWH). Inset: frequency of PLWH in each group (not significant by Fisher's exact test). (G) Univariate and (H) multivariate logistic regression odds ratios for odds of having a high neutralization response.



Figure 3: Differentially expressed proteins in neutralization and disease severity. Volcano plots show fold-change versus false discovery rate (FDR) values for each protein in two comparisons: (A) High neutralizers compared to low neutralizers; (B) severe versus non-severe disease. The x-axis represents the log fold-change between the mean protein level values in the group of high versus low neutralizers or high versus low disease severity. Y-axis is the $-log_{10}$ transformed FDR. The vertical lines indicate ± 1.5 -fold change and the horizontal line FDR=0.05. Significantly differentially expressed proteins are labeled in red (upregulated), blue (downregulated), and green (shared between responses). (C) Venn diagram showing the number of differentially expressed proteins associated with neutralization capacity and disease severity and common to both.



Figure 4: Significantly regulated pathways for neutralization and disease severity. Gene Set Enrichment Analysis (GSEA) results for significantly up or downregulated pathways in participants with high versus low neutralization capacity and those with severe versus non-severe disease. The x-axis represents the Normalized Enrichment Score (NES). Each circle represents a pathway, with the size of the circle corresponding to the $-log_{10}$ transformed FDR value, with larger circles indicating higher significance. Purple circles represent pathways enriched in the high neutralization group and orange circles represent pathways enriched in the severe disease group. One pathway (fatty acid metabolism) is shared between both groups.



Figure 5: Top differentially expressed proteins in the neutralization response show similar expression in high neutralizers regardless of disease severity. Median Z-score normalized protein levels of the top 20 differentially expressed proteins by FDR are shown for the high neutralizers with severe disease, high neutralizers with non-severe disease, and low neutralizers. Fourteen out of the 20 proteins (left) show no significant difference between the high neutralizers with severe disease versus high neutralizers with non-severe disease. Six proteins (right) show significantly higher levels in high neutralizers with severe disease relative to high neutralizers with non-severe disease. However, the levels of these proteins in low neutralizers are significantly lower still. p-values by the Kruskal-Wallis test with multiple hypothesis correction between group values per protein. Outliers with an absolute normalized expression > 3 are included in the analysis but excluded from the plot.



Figure 6: Predictive models classifying participants into high versus low neutralization groups. Shown are receiver operating characteristic (ROC) curves for (A) multivariate (HSPA8+FAP+MLN), (B) HSPA8, (C) FAP, and (D) MLN. Areas Under the Curve (AUC) were 0.91 (multivariate), 0.86 (HSP8A), 0.84 (FAP), and 0.79 (MLN). Dashed diagonal line represents the performance of a random classifier with AUC=0.50.



Figure 7: Top differentially expressed proteins in the disease severity response show similar expression regardless of neutralization capacity. Median Z-score normalized protein levels of the top 20 differentially expressed proteins by FDR are shown for the high severity group and the low severity group, with the latter divided into high and low neutralizers. Sixteen out of the 20 proteins (left) show no significant difference between non-severe high versus low neutralizers. Three proteins (middle-right) show levels in the low severity, high neutralizer group which are intermediate between participants with high severity and low severity and low neutralization. Levels of the remaining one protein show no significant difference between participants with severe disease and high neutralizers with non-severe disease. p-values by the Kruskal-Wallis test with multiple hypothesis correction between group values per protein. Outliers with an absolute normalized expression > 3 are included in the analysis but excluded from the plot.



Figure S1: Comparison of neutralization capacity of high neutralizers with low severity to participants with high disease severity. The y-axis shows $FRNT_{50}$, with bar and error bars representing the geometric mean and geometric standard deviation of each group. The horizontal dashed red line marks the limit of quantification (the inverse of the highest plasma concentration used). p-value by the non-parametric Mann-Whitney test.



Figure S2: Overlap of comorbidities and requirement for supplemental oxygen in high versus low neutralizers. Participants not requiring supplemental oxygen and having neither diabetes nor hypertension are marked in blue, those requiring supplemental oxygen but without diabetes or hypertension are in red, participants with diabetes or hypertension comorbidities only are in yellow, and those requiring both supplemental oxygen and with diabetes or hypertension comorbidities are in green. Inset shows relative frequencies of the four groups in high versus low neutralizers.



Figure S3: Significantly differentially expressed proteins in the training set. Volcano plots show fold change versus false discovery rate (FDR) values for each protein. The x-axis represents the log fold-change between the mean protein level values in the group of high versus low neutralizers or high versus low disease severity. Y-axis is the $-log_{10}$ transformed FDR. The vertical lines indicate ± 1.5 -fold change and the horizontal line FDR=0.05. Significantly differentially expressed proteins are labeled in red (upregulated) or blue (downregulated). The proteins showing highest predictive value in the model are highlighted in purple.

	Univariate		Multivariate		
	OR (95% CI)	p-value	OR (95% CI)	p-value	
$\begin{array}{c} \text{Supplemental } \mathcal{O}_2 \\ \text{Comorbidities} \\ \text{High NLR} \\ \text{Male} \\ \text{PLWH} \end{array}$	$\begin{array}{c} 6.81 \ (1.92; \ 32.3) \\ 9.78 \ (2.81; \ 46.2) \\ 7.08 \ (1.68; \ 48.9) \\ 3.27 \ (1.16; \ 9.99) \\ 0.554 \ (0.21; \ 1.43) \end{array}$	$\begin{array}{c} 0.00604 \\ 0.00102 \\ 0.0169 \\ 0.0296 \\ 0.224 \end{array}$	$\begin{array}{c} 8.04 \ (1.8; \ 47) \\ 7.61 \ (1.87; \ 40.2) \\ 3.64 \ (0.571; \ 31.5) \\ 2.66 \ (0.686; \ 11) \\ 0.476 \ (0.131; \ 1.6) \end{array}$	$\begin{array}{c} 0.0105 \\ 0.00781 \\ 0.19 \\ 0.162 \\ 0.238 \end{array}$	

 ${\bf Table \ S1:} \ {\rm Logistic \ regression \ analysis \ results}.$